Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Franchi

Showing results (111-120 of 147) with videos related to

Pageof 15
Sort By:
European Heart Journal|December 17, 2021
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trialsMattia Galli, Stefano Benenati, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|March 26, 2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 StudyFrancesco Franchi, Gabriel Todd Faz, Fabiana Rollini, et al.
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
Circulation|March 13, 2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 StudyFrancesco Franchi, Fabiana Rollini, Jose Rivas Rios, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
Circulation|January 12, 2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionFrancesco Franchi, Fabiana Rollini, Andrea Rivas, et al.
JACC. Basic to Translational Science|June 2, 2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic TestingFrancesco Franchi, Fabiana Rollini, Jose Rivas, et al.
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Thrombosis and Haemostasis|August 31, 2019
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT StudyFrancesco Franchi, Fabiana Rollini, Emilio Garcia, et al.
Pageof 15

Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
European Heart Journal|December 17, 2021
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trialsMattia Galli, Stefano Benenati, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|March 26, 2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 StudyFrancesco Franchi, Gabriel Todd Faz, Fabiana Rollini, et al.
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
Circulation|March 13, 2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 StudyFrancesco Franchi, Fabiana Rollini, Jose Rivas Rios, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
Circulation|January 12, 2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionFrancesco Franchi, Fabiana Rollini, Andrea Rivas, et al.
JACC. Basic to Translational Science|June 2, 2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic TestingFrancesco Franchi, Fabiana Rollini, Jose Rivas, et al.
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Thrombosis and Haemostasis|August 31, 2019
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT StudyFrancesco Franchi, Fabiana Rollini, Emilio Garcia, et al.
Pageof 15